Genetic and biochemical studies were carried out in 96 relatives of six independently ascertained probands with familial dysbetalipoproteinemia (FD) carrying the APOE*2 (Lys146-->Gln) allele. Compared to noncarriers, the 40 heterozygous APOE*2 (Lys146-->Gln) allele carriers exhibited markedly increased mean levels of cholesterol and triglyceride in the very low density lipoproteins (VLDL) (1.89 +/- 0.37 vs 0.30 +/- 0.27 and 1.86 +/- 0.37 vs 0.68 +/- 0.27 mmol/liter, respectively) and plasma apolipoprotein (apo) E levels (28.1 +/- 1.6 vs 4.6 +/- 1.1 mg/dl), which is characteristic for FD. By means of a pedigree-based maximum likelihood method we calculated that carrier-status accounted for 57% and 71%, respectively, of the total variance of the ratio (VLDL + IDL)-cholesterol/plasma triglyceride and plasma apoE levels. APOE*2 (Lys146-->Gln) and APOE*3-Leiden allele carriers were found to differ significantly in: (a) plasma apoE levels, (b) in the amounts of triglycerides in the VLDL and VLDL + IDL fraction, and (c) in the amount of cholesterol in the VLDL and VLDL + IDL fraction relative to the amount of triglyceride in these fractions. In the APOE*2 (Lys146-->Gln) allele carriers the VLDL and VLDL + IDL fraction is relatively rich in triglycerides as compared with that in APOE*3-Leiden carriers. We hypothesize that these two rare mutations of apoE both lead to dominantly inherited forms of FD along different underlying metabolic defects.
P de Knijff, A M van den Maagdenberg, D I Boomsma, A F Stalenhoef, A H Smelt, J J Kastelein, A D Marais, R R Frants, L M Havekes
Title and authors | Publication | Year |
---|---|---|
Establishing the relationship between familial dysbetalipoproteinemia and genetic variants in the APOE gene.
Heidemann BE, Koopal C, Baass A, Defesche JC, Zuurbier L, Mulder MT, Roeters van Lennep JE, Riksen NP, Boot C, Marais AD, Visseren FLJ |
Clinical Genetics | 2022 |
Autosomal dominant familial dysbetalipoproteinemia: A pathophysiological framework and practical approach to diagnosis and therapy
C Koopal, AD Marais, J Westerink, FL Visseren |
Journal of Clinical Lipidology | 2016 |
Role of apolipoprotein E in neurodegenerative diseases
VV Giau, E Bagyinszky, SS An, SY Kim |
Neuropsychiatric Disease and Treatment | 2015 |
Apolipoprotein ε2/3 genotype and type III hyperlipoproteinemia among Taiwanese
HP Lin, JT Kao |
Clinica Chimica Acta | 2003 |
Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia
M Dam, M Zwart, F Beer, AH Smelt, MH Prins, MD Trip, LM Havekes, PJ Lansberg, JJ Kastelein |
Heart (British Cardiac Society) | 2002 |
Molecular genetics and gene expression in atherosclerosis
PA Doevendans, W Jukema, W Spiering, JC Defesche, JJ Kastelein |
International Journal of Cardiology | 2001 |
Apolipoprotein E2 (Lys146→Gln) Causes Hypertriglyceridemia due to an Apolipoprotein E Variant–Specific Inhibition of Lipolysis of Very Low Density Lipoproteins–Triglycerides
F de Beer, KW van Dijk, MC Jong, LC van Vark, A van der Zee, MH Hofker, FJ Fallaux, RC Hoeben, AH Smelt, LM Havekes |
Arteriosclerosis, thrombosis, and vascular biology | 2000 |
Application of electrophoretic techniques to the diagnosis of disorders of lipoprotein metabolism. Examples at the levels of lipoproteins and apolipoproteins
W Groß, W März |
Analytica Chimica Acta | 1999 |
Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries, and paradoxes
RW Mahley, Y Huang, SC Rall |
Journal of lipid research | 1999 |
Relevance of Apolipoprotein E Polymorphism for Coronary Artery Disease in the Saudi Population
N Dzimiri, BF Meyer, SS Hussain, C Basco, B Afrane, Z Halees |
Archives of pathology & laboratory medicine | 1999 |
Dissection of the complex role of apolipoprotein E in lipoprotein metabolism and atherosclerosis using mouse models
KW van Dijk, MH Hofker, LM Havekes |
Current Atherosclerosis Reports | 1999 |
GENETICS OF LIPOPROTEIN DISORDERS
J Davignon, J Genest |
Endocrinology & Metabolism Clinics of North America | 1998 |
Effect of apolipoprotein E variants on lipolysis of very low density lipoproteins by heparan sulphate proteoglycan-bound lipoprotein lipase
FH de Man, F Beer, A der Laarse, AH Smelt, JA Leuven, LM Havekes |
Atherosclerosis | 1998 |
The Apolipoprotein E2(Arg145Cys) Mutation Causes Autosomal Dominant Type III Hyperlipoproteinemia With Incomplete Penetrance
WJ de Villiers, DR van der Westhuyzen, GA Coetzee, HE Henderson, AD Marais |
Arteriosclerosis, thrombosis, and vascular biology | 1997 |
Modulation of very low density lipoprotein production and clearance contributes to age- and gender- dependent hyperlipoproteinemia in apolipoprotein E3-Leiden transgenic mice
BJ van Vlijmen, HB van Hof, MJ Mol, H der Boom, A der Zee, RR Frants, MH Hofker, LM Havekes |
Journal of Clinical Investigation | 1996 |
Apolipoprotein E1-Hammersmith (Lys146 → Asn;Arg147 → Trp), due to a dinucleotide substitution, is associated with early manifestation of dominant type III hyperlipoproteinaemia
MJ Hoffer, S Niththyananthan, RP Naoumova, MS Kibirige, RR Frants, LM Havekes, GR Thompson |
Atherosclerosis | 1996 |